New perspectives for cancer therapy
Immunotherapy for cancer at the IOZK in Cologne
In recent decades, the field of tumor immunology has been the subject of intensive research worldwide. The Nobel Prize in Medicine was awarded in 2011 and 2018 for discoveries in immuno-oncology, demonstrating the outstanding importance of this discipline. Since 1985, our physicians and scientists at the Immun-Onkologisches Zentrum Köln (IOZK) have been studying the role of the immune system in cancer and chronic infectious diseases.
Based on these findings, we have developed the IOZK immunotherapy. It is strictly scientifically oriented: all methods used are grounded in well-established findings in tumor biology and immuno-oncology.
The goal of IOZK immunotherapy is to specifically activate the patient’s own immune system against cancer. Ideally, it can provide long-term protection against the growth of new cancer cells. Established treatments such as surgery, chemotherapy, and radiation therapy aim to destroy the tumor through surgery or medication—often with side effects that affect healthy cells and the immune system.
IOZK immunotherapy can be combined with all conventional cancer treatments. Through years of clinical application and research, it has proven to be gentle and very well tolerated because it specifically targets only cancer cells and largely spares healthy cells.
We are committed to further developing IOZK immunotherapy in light of new findings in immuno-oncology. We are already able to offer our patients treatment options that are not yet considered standard of care.
Depending on the terms of the contract, some private health insurance plans or workers' compensation associations may cover the costs. Under certain conditions, statutory health insurance plans may also cover the fees.
Andreas Wellander
